Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Actinium Pharmaceuticals Inc ATNM

Healthcare Biotechnology
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A... see more

Recent & Breaking News (NYSEAM:ATNM)

Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML

PR Newswire March 25, 2021

Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy

PR Newswire March 24, 2021

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC

PR Newswire March 11, 2021

Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer

PR Newswire March 3, 2021

Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference

PR Newswire March 2, 2021

Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting

PR Newswire February 11, 2021

Actinium Announces Participation in BIO CEO & Investor Digital Conference

PR Newswire February 10, 2021

Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference

PR Newswire January 20, 2021

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies

PR Newswire January 13, 2021

Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial

PR Newswire December 29, 2020

Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit

PR Newswire December 9, 2020

Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH

PR Newswire December 8, 2020

Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting

PR Newswire December 7, 2020

Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting

PR Newswire December 7, 2020

Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting

PR Newswire December 7, 2020

Actinium Highlights Clinical Data to be Presented at the Upcoming 62nd American Society of Hematology Annual Meeting

PR Newswire December 3, 2020

Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development

PR Newswire December 1, 2020

Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity

PR Newswire November 23, 2020

Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs

PR Newswire November 19, 2020

Actinium to Participate in the Alliance Global Partners' Virtual Healthcare Symposium

PR Newswire November 16, 2020